000142590 001__ 142590
000142590 005__ 20240229111726.0
000142590 0247_ $$2doi$$a10.1093/eurheartj/ehy167
000142590 0247_ $$2pmid$$apmid:29635274
000142590 0247_ $$2ISSN$$a0195-668X
000142590 0247_ $$2ISSN$$a1522-9645
000142590 0247_ $$2altmetric$$aaltmetric:35991516
000142590 037__ $$aDKFZ-2019-00308
000142590 041__ $$aeng
000142590 082__ $$a610
000142590 1001_ $$0P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aWeberpals, Janick$$b0$$eFirst author$$udkfz
000142590 245__ $$aLong-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study.
000142590 260__ $$aOxford$$bOxford University Press$$c2018
000142590 3367_ $$2DRIVER$$aarticle
000142590 3367_ $$2DataCite$$aOutput Types/Journal article
000142590 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550671020_25980
000142590 3367_ $$2BibTeX$$aARTICLE
000142590 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142590 3367_ $$00$$2EndNote$$aJournal Article
000142590 520__ $$aBreast cancer survival has improved throughout the last decades, but treatment-induced cardiotoxicity remains a major concern. This study aimed to investigate competing causes of death and prognostic factors within a large cohort of breast cancer patients and to describe the heart-specific mortality in relation to the general population.In this registry-based cohort study, women diagnosed with breast cancer between 2000 and 2011, who were treated with radiotherapy or chemotherapy and followed until 2014, were identified from the Surveillance, Epidemiology, and End Results-18 (SEER-18) database. Cumulative mortality functions were computed. To investigate heart-specific mortality relative to the general population, long-term (≥10 years) standardized mortality ratios (SMRs) were calculated. Prognostic factors for heart-specific mortality were assessed by calculating cause-specific hazard ratios (HRcs) with corresponding 95% confidence intervals using the Cox proportional hazards regression. Subgroup analysis on intermediate-term mortality according to molecular subtypes, for which information was available since 2010, was performed. In total, 347 476 breast cancer patients were eligible to be included in the study. Among all possible competing causes of death, breast cancer accounted for the highest cumulative mortality. Compared with the general population, heart-specific mortality of breast cancer patients treated with radiotherapy or chemotherapy was lower [SMRoverall 0.84 (0.79-0.90)]. In subgroup analysis, human epidermal growth factor receptor 2 (HER2)-positive subtype was not associated with increased heart-specific mortality relative to HER2-negative patients [HRcs 0.96 (0.70-1.32)].Heart-specific mortality among breast cancer survivors is not increased compared with the general population. Human epidermal growth factor receptor 2-positive patients do not have increased heart-specific mortality compared to HER2-negative patients.
000142590 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000142590 588__ $$aDataset connected to CrossRef, PubMed,
000142590 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000142590 7001_ $$aMüller, Oliver J$$b2
000142590 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000142590 773__ $$0PERI:(DE-600)2001908-7$$a10.1093/eurheartj/ehy167$$gVol. 39, no. 43, p. 3896 - 3903$$n43$$p3896 - 3903$$tEuropean heart journal$$v39$$x1522-9645$$y2018
000142590 909CO $$ooai:inrepo02.dkfz.de:142590$$pVDB
000142590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142590 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000142590 9141_ $$y2018
000142590 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142590 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142590 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142590 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142590 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142590 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR HEART J : 2017
000142590 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142590 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142590 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142590 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142590 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142590 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142590 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bEUR HEART J : 2017
000142590 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000142590 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000142590 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000142590 980__ $$ajournal
000142590 980__ $$aVDB
000142590 980__ $$aI:(DE-He78)C070-20160331
000142590 980__ $$aI:(DE-He78)G110-20160331
000142590 980__ $$aI:(DE-He78)L101-20160331
000142590 980__ $$aUNRESTRICTED